{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:21:09Z","timestamp":1788236469263,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-16-00013163"],"award-info":[{"award-number":["G-16-00013163"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-159928"],"award-info":[{"award-number":["FDN-159928"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtha.2025.05.032","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:17:07Z","timestamp":1749237427000},"page":"2830-2836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["DOAC\u2013Stop reverses the anticoagulant effect of asundexian and milvexian"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3273-9661","authenticated-orcid":false,"given":"Ella K.","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.05.032_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.05.032_bib2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/ph16060866","article-title":"Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances","volume":"16","author":"Xia","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jtha.2025.05.032_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.032_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.032_bib5","year":"2025"},{"key":"10.1016\/j.jtha.2025.05.032_bib6","series-title":"A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, for stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack","year":"2025"},{"key":"10.1016\/j.jtha.2025.05.032_bib7","series-title":"A phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, after a recent acute coronary syndrome","year":"2025"},{"key":"10.1016\/j.jtha.2025.05.032_bib8","series-title":"A phase 3, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian, an oral factor XIa inhibitor, versus apixaban in participants with atrial fibrillation","year":"2025"},{"key":"10.1016\/j.jtha.2025.05.032_bib9","year":"2025"},{"key":"10.1016\/j.jtha.2025.05.032_bib10","series-title":"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE","year":"2024"},{"key":"10.1016\/j.jtha.2025.05.032_bib11","series-title":"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab vs. dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with GI associated VTE","year":"2024"},{"key":"10.1016\/j.jtha.2025.05.032_bib12","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2025.05.032_bib13","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1182\/bloodadvances.2022009236","article-title":"Histidine-rich glycoprotein attenuates catheter thrombosis","volume":"7","author":"Malik","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.05.032_bib14","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.032_bib15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.032_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.032_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/rth2.12472","article-title":"DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples","volume":"5","author":"Baker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.032_bib18","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1055\/s-0038-1657785","article-title":"Evaluation of the DOAC-Stop\u00ae procedure to overcome the effect of DOACs on several thrombophilia screening tests","volume":"2","author":"Favresse","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.05.032_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2018.01.047","article-title":"Simple method for removing DOACs from plasma samples","volume":"163","author":"Exner","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.032_bib20","doi-asserted-by":"crossref","first-page":"O171","DOI":"10.1111\/ijlh.13487","article-title":"The effect of DOAC-Stop\u00ae on several oral and parenteral anticoagulants","volume":"43","author":"Riva","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.05.032_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2025.05.032_bib22","series-title":"Activated carbon: fundamentals, classification, and properties","first-page":"1","author":"Ganjoo","year":"2023"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:02:38Z","timestamp":1788235358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1538783625003563"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.032","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DOAC\u2013Stop reverses the anticoagulant effect of asundexian and milvexian","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.030","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}